Share useful research with your peers
in · Share on LinkedIn ↗
BIOTECH ASSISTANT / FIELD NOTES

Labcorp poster describes a direct format for neutralizing anti-drug antibody assays

Company / institutional announcement · Labcorp

Source published: · Event / reporting date: 2026-10-30

Site published: 2026-11-06 · Updated: 2026-11-06

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

Labcorp posted a CBF 2026 conference-poster summary describing a direct assay format for neutralizing anti-drug antibodies. The approach is intended to address limitations of competitive assays when drug–target affinity is weak or signals are unstable. The public summary presents the assay concept, rather than quantitative validation results or a peer-reviewed clinical study.

Why it may matter

Analysis: A direct format may offer an alternative assay-development route when competitive binding limits performance, subject to fit-for-purpose validation.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Bioanalysis & Biomarkers

Follow the evidence

Related updates

Bioanalysis

Multiplex assay separates domain-specific ADA responses using a PEGylated Cas9 model

A Bioanalysis paper describes development and prevalidation of a Luminex xMAP assay for simultaneous domain-specific anti-drug antibody detection. Using PEGylated Cas9 as a model, the authors report adjustable bead ratios and on-demand coupling to accommodate different minimum required dilutions. The original abstract supports assay feasibility, rather than universal validation across multidomain therapeutics or demonstrated clinical benefit.

Labcorp

Labcorp poster evaluates orthogonal RNA and DNA integrity checks for CGT bioanalysis

Labcorp published a conference-poster summary on independent RNA and DNA integrity assessment in cell and gene therapy bioanalysis. It evaluates Agilent TapeStation microfluidic electrophoresis as an orthogonal quality-control tool alongside qPCR and RT-qPCR, which do not directly measure overall integrity. The public summary describes the evaluation's objective and rationale, without quantitative performance results or peer-reviewed publication metadata.

Bioanalysis / PubMed

Review explains statistical pitfalls in anti-drug antibody assay cut points

Based on the PubMed abstract, this review explains how sample selection, experimental balance, outlier handling, transformation, and statistical methods affect anti-drug antibody assay cut points. It addresses screening, confirmation, titers, drug tolerance, and reassessment using clinical baseline samples. This is a practical review of validation decisions, not a new clinical efficacy study.

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗
AI assistant ↗